Nishikawa K, Reddigari S R, Silverberg M, Kuna P B, Yago H, Nagaki Y, Toyomaki Y, Suehiro S, Kaplan A P
Department of Medicine, State University of New York, Stony Brook 11794-8161.
Biochem Pharmacol. 1992 Mar 17;43(6):1361-9. doi: 10.1016/0006-2952(92)90514-j.
Bradykinin (BK), an important mediator of allergic reactions and pain induction, is released by the activation of the plasma kallikrein-kinin (K-K) cascade. Neurotropin is a biological material obtained from inflamed rabbit skin inoculated with vaccinia virus and is widely used clinically in Japan as an effective agent for these disorders. Since its mechanism of action is not clearly known, we have investigated the effects of Neurotropin on the human plasma K-K system. In dextran sulfate-activated plasma, Neurotropin inhibited the formation of BK, the cleavage of high molecular weight kininogen (HK) and the formation of kallikrein-C1 inhibitor and activated coagulation factor XII (FXIIa)-C1 inhibitor complexes. Experiments using purified enzyme of the K-K cascade indicated that Neurotropin inhibited surface-mediated activation of coagulation factor XII (FXII) and the activation of prekallikrein by FXIIa. Neurotropin also inhibited the binding of FXII and HK to the activating surface. These data suggest that the ameliorating effects of Neurotropin in allergic disorders and pain syndromes may be related to this ability to inhibit activation of the K-K cascade and consequently the formation of BK.
缓激肽(BK)是过敏反应和疼痛诱导的重要介质,由血浆激肽释放酶 - 激肽(K - K)级联反应的激活而释放。神经妥乐平是一种从接种痘苗病毒的炎症兔皮肤中获得的生物材料,在日本临床上广泛用作治疗这些疾病的有效药物。由于其作用机制尚不清楚,我们研究了神经妥乐平对人血浆K - K系统的影响。在硫酸葡聚糖激活的血浆中,神经妥乐平抑制BK的形成、高分子量激肽原(HK)的裂解以及激肽释放酶 - C1抑制剂和活化凝血因子XII(FXIIa) - C1抑制剂复合物的形成。使用K - K级联反应的纯化酶进行的实验表明,神经妥乐平抑制凝血因子XII(FXII)的表面介导激活以及FXIIa对前激肽释放酶的激活。神经妥乐平还抑制FXII和HK与激活表面的结合。这些数据表明,神经妥乐平在过敏性疾病和疼痛综合征中的改善作用可能与其抑制K - K级联反应激活并因此抑制BK形成的能力有关。